Status:

COMPLETED

BRain Energy Activation With Ketones to Prevent Alzheimer's Disease

Lead Sponsor:

Université de Sherbrooke

Collaborating Sponsors:

Alzheimer's Association

Nestle Health Science

Conditions:

MCI

Eligibility:

All Genders

55-80 years

Phase:

NA

Brief Summary

A six month randomized controlled intervention with an exogenous ketone salt (EKS) supplement in mild cognitive impairment. Participants will receive 15 g of the supplement twice daily (equivalent to ...

Eligibility Criteria

Inclusion

  • The participant must answer Yes to the question ''Do you think your memory is not as good as it was?''
  • Have a MoCA Score between 20/30 and 26/30
  • Have a QAF score of less than 9/30
  • Understand, read and talk French
  • Having good visual and hearing acuity

Exclusion

  • Major cognitive decline or neurodegenerative disease.
  • Already consuming a daily medium chain triglyceride or ketone supplement.
  • Soy, milk, gluten or allergy to the study product
  • Controlled or uncontrolled diabetes
  • Uncontrolled chronic disease
  • Vitamin B12 deficit
  • Clinical anomaly in the blood chemistry profile
  • QSP-9 score over 19/27
  • Taking an anti-cholinergic drugs
  • Recent change in medication
  • Active cancer in the last 2 years
  • General anesthesia in the last 6 months
  • history of alcohol abuse or dependence in the last 2 years
  • Participation in other interventional or PET research project
  • Unable to undergo an MRI or PET scan
  • History of kidney stones or hypercalcemia
  • History of cardiovascular events or insufficiency
  • Renal failure and / or creatinine \<58 umol or\> 110 umol for men and \<46 umol or\> 92 umol for women or if the GFR (glomerular filtration rate) \<60 ml / min / 1.73 m2
  • Chronic disease of the digestive system or intestinal malabsorption (celiac disease, chronic pancreatitis, Crohn's disease, etc.)
  • Body mass index \<20 or voluntary weight loss of more than 5% in the last 6 months.

Key Trial Info

Start Date :

October 15 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 10 2025

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT04466735

Start Date

October 15 2020

End Date

March 10 2025

Last Update

June 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rearsh Centre on Aging

Sherbrooke, Quebec, Canada, J1H4C4